Last Price$488.3(2.3%)
Market Cap$124.8B
LTM Pre-tax Income
$248.5M
YoY Growth
-94.3%
3Y CAGR
-55.0%
5Y CAGR
-29.2%
Stock quality & Intrinsic value
6/10
61.6% overvalued
Vertex Pharmaceuticals Incorporated Pre-tax Income
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-tax Income | ($173.4M) | ($206.9M) | ($426.9M) | ($464.2M) | ($642.2M) | ($754.6M) | $60.4M | ($12.4M) | ($976.1M) | ($734.9M) | ($559.6M) | ($67.4M) | ($15.7M) | $600.2M | $1,394.9M | $3,116.8M | $2,730.4M | $4,232.4M | $4,379.8M | $248.5M |
Overvalued or undervalued?
Check the intrinsic value for VRTX
and see if it's the right time to invest.
Vertex Pharmaceuticals Incorporated (VRTX) Pre-tax Income comparison analysis
General
LTM Pre-tax Income
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Vertex Pharmaceuticals IncorporatedVRTX
$248.5M
(94.3%)
(55.0%)
(29.2%)
Median Peer Set
$127.9M
(12.4%)
0.0%
(0.5%)
Regeneron Pharmaceuticals, Inc.REGN
$4,779.9M
13.8%
(20.0%)
14.5%
United Therapeutics CorporationUTHR
$1,539.0M
20.8%
37.4%
N/A
Royalty Pharma plcRPRX
$1,330.5M
(21.8%)
2.3%
(11.6%)
BioMarin Pharmaceutical Inc.BMRN
$541.8M
187.3%
N/A
N/A
Incyte CorporationINCY
$316.6M
(62.0%)
(17.8%)
(8.2%)
argenx SEARGX
($60.8M)
(78.6%)
N/A
(10.3%)
Summit Therapeutics Inc.SMMT
($221.4M)
(64.0%)
35.7%
48.4%
Alnylam Pharmaceuticals, Inc.ALNY
($377.4M)
(13.0%)
(23.8%)
(15.7%)
BioNTech SEBNTX
($733.1M)
N/A
N/A
30.4%
BeiGene, Ltd.BGNE
($798.4M)
(11.9%)
(15.7%)
(1.0%)
VRTX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 160.9 56.6% | 216.4 34.5% | 199.0 (8.0%) | 175.5 (11.8%) | 102.0 (41.9%) | 143.4 40.5% | 1,410.6 883.9% | 1,527.0 8.3% | 1,212.0 (20.6%) | 580.4 (52.1%) | 1,032.3 77.9% | 1,702.2 64.9% | 2,488.7 46.2% | 3,047.6 22.5% | 4,162.8 36.6% | 6,205.7 49.1% | 7,574.4 22.1% | 8,930.7 17.9% | 9,869.2 10.5% | 11,020.1 11.7% |
| Cost of Goods Sold (COGS) | 10.1 | 12.2 | 13.9 | 15.7 | 14.2 | 12.7 | 80.5 | 279.9 | 130.3 | 61.0 | 125.5 | 210.5 | 275.1 | 409.5 | 547.8 | 736.3 | 904.2 | 1,080.3 | 1,262.2 | 1,530.5 |
% margin | 150.8 93.7% | 204.2 94.4% | 185.1 93.0% | 159.8 91.1% | 87.8 86.1% | 130.6 91.1% | 1,330.1 94.3% | 1,247.2 81.7% | 1,081.7 89.3% | 519.4 89.5% | 906.8 87.8% | 1,491.7 87.6% | 2,213.5 88.9% | 2,638.1 86.6% | 3,615.1 86.8% | 5,469.4 88.1% | 6,670.2 88.1% | 7,850.4 87.9% | 8,607.0 87.2% | 9,489.6 86.1% |
| Operating Expenses | 292.5 | 429.6 | 597.8 | 618.2 | 680.0 | 825.2 | 1,108.4 | 1,243.0 | 1,281.1 | 1,160.9 | 1,373.3 | 1,480.5 | 1,820.7 | 1,974.1 | 2,413.0 | 2,600.0 | 3,891.2 | 3,485.0 | 4,775.0 | 9,722.5 |
| Research & Development Expenses (R&D) | 248.5 | 371.7 | 513.1 | 516.3 | 550.7 | 637.4 | 707.7 | 806.2 | 918.8 | 855.5 | 996.2 | 1,047.7 | 1,324.6 | 1,416.5 | 1,754.5 | 1,829.5 | 3,051.1 | 2,540.3 | 3,162.9 | 3,630.3 |
| Selling, General & Administrative Expenses (SG&A) | 44.0 | 57.9 | 84.7 | 101.9 | 129.3 | 187.8 | 400.7 | 436.8 | 362.3 | 305.4 | 377.1 | 432.8 | 496.1 | 557.6 | 658.5 | 770.5 | 840.1 | 944.7 | 1,136.6 | 1,464.3 |
% margin | (149.9) (93.2%) | (229.0) (105.9%) | (419.8) (210.9%) | (462.7) (263.6%) | (613.4) (601.1%) | (696.1) (485.5%) | 113.8 8.1% | 2.3 0.2% | (903.4) (74.5%) | (692.4) (119.3%) | (468.7) (45.4%) | 9.9 0.6% | 123.2 5.0% | 635.2 20.8% | 1,197.6 28.8% | 2,856.3 46.0% | 2,782.1 36.7% | 4,307.4 48.2% | 4,307.5 43.6% | (232.9) (2.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 16.3 | 5.0 | 2.0 | 1.9 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 11.7 | 0.0 | 63.7 | 22.2 | 4.9 | 144.6 | 614.7 | 598.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 13.5 | 13.2 | 19.3 | 36.6 | 14.7 | 22.7 | 72.9 | 84.2 | 81.4 | 57.6 | 34.1 | 58.5 | 58.2 | 61.5 | 54.8 | 44.1 | 30.6 |
| Pre-tax Income | (173.4) | (206.9) | (426.9) | (464.2) | (642.2) | (754.6) | 60.4 | (12.4) | (976.1) | (734.9) | (559.6) | (67.4) | (15.7) | 600.2 | 1,394.9 | 3,116.8 | 2,730.4 | 4,232.4 | 4,379.8 | 248.5 |
% effective tax rate | 61.7 (35.6%) | (18.5) 8.9% | (21.4) 5.0% | (30.7) 6.6% | 19.3 (3.0%) | 19.3 (2.6%) | 19.3 31.9% | 38.8 (313.0%) | (288.6) 29.6% | 7.0 (0.9%) | 30.4 (5.4%) | 16.7 (24.7%) | (107.3) 684.1% | (1,486.9) (247.7%) | 218.1 15.6% | 405.2 13.0% | 388.3 14.2% | 910.4 21.5% | 760.2 17.4% | 784.1 315.5% |
% margin | (203.4) (126.4%) | (206.9) (95.6%) | (391.3) (196.6%) | (459.9) (262.0%) | (641.6) (628.7%) | (754.6) (526.3%) | 29.6 2.1% | (107.0) (7.0%) | (445.0) (36.7%) | (738.6) (127.2%) | (558.1) (54.1%) | (112.1) (6.6%) | 263.5 10.6% | 2,096.9 68.8% | 1,176.8 28.3% | 2,711.7 43.7% | 2,342.1 30.9% | 3,322.0 37.2% | 3,619.6 36.7% | (535.6) (4.9%) |
| EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.32) | (0.46) | 1.06 | 8.25 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | (2.08) |
| Diluted EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.31) | (0.46) | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | (2.08) |
% margin | (114.4) (71.1%) | (199.5) (92.2%) | (385.2) (193.6%) | (426.2) (242.8%) | (598.9) (586.9%) | (704.9) (491.7%) | 133.9 9.5% | 42.5 2.8% | (554.8) (45.8%) | (598.8) (103.2%) | (411.3) (39.8%) | 75.5 4.4% | 103.3 4.1% | 706.8 23.2% | 1,560.4 37.5% | 3,284.5 52.9% | 2,917.5 38.5% | 4,435.5 49.7% | 4,605.2 46.7% | 486.3 4.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Vertex Pharmaceuticals Incorporated's Pre-tax Income?
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Pre-tax Income is $248.5M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Vertex Pharmaceuticals Incorporated's Pre-tax Income growth rate?
Over the last year, Vertex Pharmaceuticals Incorporated's Pre-tax Income growth was (94.3%). The average annual Pre-tax Income growth rates for Vertex Pharmaceuticals Incorporated have been (53.1%) over the past three years, (29.2%) over the past five years.
3) Is Vertex Pharmaceuticals Incorporated's Pre-tax Income growth rate Good?
Over the last year, Vertex Pharmaceuticals Incorporated's Pre-tax Income growth was (94.3%), which is lower than industry growth of (0.1%). It indicates that Vertex Pharmaceuticals Incorporated's Pre-tax Income growth is Bad.